Even the most dedicated cancer teams can miss patients who need navigation, genetic counseling, or tumor board review. Traditional systems like the EHR and cancer registry weren’t designed to provide real-time, proactive visibility—leaving high-risk patients at risk of falling through the cracks.
At an academic comprehensive cancer center in Florida, that changed with the introduction of the OncoLens Registry Report. Within just one week of use, the team uncovered 17 rectal cancer patients under age 50—14 of whom had been completely overlooked by standard systems. These findings not only enabled immediate, potentially life-saving interventions but also transformed how the team manages quality initiatives, tumor board planning, and compliance with national accreditation standards.
This case study highlights how structured, real-time data can power faster, smarter decision-making across multiple cancer programs—turning guesswork into action.
Download the full case study to see how the Registry Report redefined patient visibility, improved compliance, and scaled quality across cancer types.
When patients face delays in critical consultations, the entire care journey can be disrupted—leading to unnecessary stress, extended timelines, and potential compliance risks. One academic comprehensive cancer center in Florida knew these delays were happening but lacked the data to measure, prove, and solve the problem.
By partnering with OncoLens, the center implemented a Referral Report that delivered real-time visibility into referral-to-consult timelines. The results were immediate and measurable: faster interventions, stronger compliance with NAPBC standards, and improved patient experiences. Beyond solving delays, the data also helped the team reimagine capacity planning, optimize scheduling protocols, and create decision trees aligned with treatment pathways.
This case study reveals how the Referral Report shifted their operations from reactive to proactive, offering a model that can be applied across other specialties and pathways.
Complete the form to download the full case study to see how actionable referral data reduced delays, improved compliance, and reshaped patient care coordination.
Unlock the future of clinical trial recruitment with an AI-driven solution that identifies the right patients with unprecedented speed and precision.
OncoLens leverages specialized AI, Natural Language Processing, and Large Language Models (LLMs) to revolutionize patient pre-screening for oncology clinical trials. By seamlessly mining both structured and unstructured data, this innovative approach not only distinguishes complex medical nuances—like differentiating between an emergency room visit and an estrogen receptor status—but also dramatically reduces manual chart review time. This study highlights real-world applications in challenging trials such as diffuse large B-cell lymphoma and lungMAP, demonstrating significant efficiency gains and improved patient accrual. With a human-in-the-loop model ensuring nuanced review and continuous re-screening of patient records, OncoLens paves the way for faster, more accurate trial matching and ultimately accelerates the journey to personalized cancer care. Download this case study to learn more.
Complete our quick form to download and read the full case study.
Learn how OncoLens Analytics enabled a rural community cancer center to achieve a 350% increase in genetic testing for breast cancer patients.
By integrating AI and advanced NLP technology, the center was able to identify eligible patients swiftly and accurately, enhancing workflows and improving patient outcomes. The study highlights the critical role of timely genetic testing in precision cancer care and the benefits of AI-driven healthcare solutions. Download the full case study to learn more about the transformative impact of OncoLens on cancer treatment and patient care. Download this case study to learn more.
Complete our quick form to download and read the full case study.
Discover how a cutting-edge quality improvement initiative is transforming lung cancer care by optimizing biomarker testing to deliver faster, more accurate treatment decisions.
OncoLens showcases the remarkable impact of a multidisciplinary quality improvement program (QIP) designed to elevate comprehensive lung cancer biomarker testing rates. Focused on advanced non-small cell lung cancer, the initiative—implemented by Bon Secours Mercy Health—integrated innovative liquid biopsy techniques with traditional tissue sampling to overcome testing limitations and reduce delays. By updating pathology-driven testing panels and streamlining workflows through a single reference lab partnership, the program not only boosted comprehensive testing rates but also significantly shortened the time from diagnosis to actionable results. This evidence-based approach not only enhances targeted therapy selection but also improves overall patient outcomes, making it a compelling model for health systems aiming to deliver state-of-the-art oncology care. Download this case study to learn more.
Complete our quick form to download and read the full case study.
Through expert-led discussions, clinicians will learn how to engage multidisciplinary teams (MDTs) to enhance gastroesophageal (GE) cancer care coordination, from diagnosis to treatment. The program will emphasize the use of molecular profiling and biomarker testing to guide personalized treatment plans, focusing on actionable mutations and key biomarkers in GE cancers. Through case-based scenarios, faculty will explore how key molecular findings and patient/tumor characteristics influence treatment decisions, striving towards optimized outcomes for patients with GE cancers.
Gastric Cancer: Enhanced Clinical Decision-Making Via Molecular Profiling
ACTIVITY CHAIR:
Samuel J. Klempner, MD
Director, Gastroesophageal Medical Oncology
Associate Professor, Harvard Medical School
Mass General Cancer Center
Boston, MA
FACULTY:
Yelena Y. Janjigian, MD
Attending Physician
Professor, Weill Cornell Medical College
Chief, Gastrointestinal Oncology Service
Memorial Sloan Kettering Cancer Center
New York, NY
Target Audience
The intended audience for this activity is primarily US-based community oncologists and hematologist-oncologists involved in the management of patients with solid tumor cancers, and secondarily, additional members of community oncology care teams.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
Use appropriate methods for biomarker testing to better guide clinical decision-making.
Individualize treatment plans for patients with advanced solid tumors based on the latest evidence as well as patient and tumor characteristics.
Use MDT strategies to improve coordination of care for patients undergoing anti-cancer therapy.
Accreditation / Designation of Credit
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is approved for 1 year from the date of original release, December 31, 2024, to December 30, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Through expert-led discussions, clinicians will learn how to engage multidisciplinary teams (MDTs) to enhance non-small cell lung cancer (NSCLC) care coordination, from diagnosis to treatment. The program will emphasize the use of molecular profiling and biomarker testing to guide personalized treatment plans, focusing on actionable mutations and key biomarkers in NSCLC. Through case-based scenarios, faculty will explore how key molecular findings and patient/tumor characteristics influence treatment decisions, striving toward optimized outcomes for patients with NSCLC.
NSCLC: Individualizing Care Based on Patient and Tumor Characteristics
ACTIVITY CHAIR:
Charu Aggarwal, MD, MPH
Leslye M. Heisler Professor of Medicine
Section Chief, Thoracic and Head & Neck Cancer
Assoc. Director, Penn Center for Cancer Care Innovation (PC3I)
University of Pennsylvania
Philadelphia, PA
FACULTY:
Brian S. Henick, MD
Interim Director, Experimental Therapeutics
Director, Translational Research, Upper-Aerodigestive Malignancies, Medical Oncology
Assistant Professor of Medicine at Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, NY
Target Audience
The intended audience for this activity is primarily US-based community oncologists and hematologist-oncologists involved in the management of patients with solid tumor cancers, and secondarily, additional members of community oncology care teams.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
Use appropriate methods for biomarker testing to better guide clinical decision-making.
Individualize treatment plans for patients with advanced solid tumors based on the latest evidence as well as patient and tumor characteristics.
Use MDT strategies to improve coordination of care for patients undergoing anticancer therapy.
Accreditation / Designation of Credit
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This enduring material is approved for 1 year from the date of original release, December 31, 2024, to December 30, 2025.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 6 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
The Lung-MAP trial also known as the Lung Cancer Master Protocol, is a precision medicine clinical trial designed for people with advanced non-small cell lung cancer (NSCLC) that has continued to grow after treatment. Enrollment in the Lung-MAP trial can provide critical access to targeted therapies for clinically appropriate patients.
One barrier to patient enrollment is the trial’s complex screening criteria, which vary based on whether the patient is currently in stage 1 to 3, or stage 4. For patients to be eligible to enroll, they must have progressed on platinum-based therapy if they are currently metastatic or have progressed within one year of initiation of such therapy for patients who are not metastatic at diagnosis.
The need to monitor these criteria can be a barrier to research teams to identify patients in time. Utilizing AI-driven, automated mechanisms to identify individuals in the early stages of lung cancer who show signs of progression can help mitigate this problem. By monitoring these patients early on, through automated, real-time reports, patients can be identified, educated and pre-screened early.
In a recent implementation of OncoLens Patient ID, a digital pre-screening and tracking solution that combs through structured and unstructured EMR data and matching those to the trial’s inclusion/exclusion criteria, 8% of lung cancer patients were found to be potential candidates for the trial and placed in a tracking queue. 2% ultimately accrued while simultaneously reducing the time to find patients from 5 hours per week to less than 30 minutes.
OncoLens, a leader in optimizing cancer treatment planning, announced it has raised $16 million in a Series B round co-led by BIP Capital and Cross Border Impact Ventures. Martin Ventures and SeedToB, existing investors in the company, also participated in this round.
ATLANTA, Oct. 24, 2024 /PRNewswire-PRWeb/ — The Series B funding comes on the heels of the company coming in at No. 1296 on the Inc 5000’s 2024 list of fastest growing privately held companies in America. The company serves national cancer institutes (NCIs), academic medical centers and community based integrated delivery networks (IDNs) with the mission of delivering timely, precision cancer care.
The company delivers on this mission through AI enabled clinical and workflow solutions across three pillars of multidisciplinary collaboration, data interoperability and AI driven informatics. OncoLens’ proprietary and unique oncology focused AI capabilities provide cancer centers the ability to extract key insights from structured or unstructured clinical, molecular and other lab data to find patients who might have missed treatment-defining diagnostics or therapies, in real time. OncoLens’ collaboration solutions can then be used to coordinate next steps on those patients to ensure action is taken in a timely and multidisciplinary manner. The focus on a comprehensive set of solutions delivering intelligence and efficiency has set the company apart.
“OncoLens’ focus on not just delivering insights but usability tools such as provider targeted alerts, continues to excite us along with their already impressive growth.”
OncoLens serves care providers internationally as well, having launched in the EMEA (Europe, Middle East and Africa) region in 2022. With the growth of its customer base, the company launched the OncoLens Research Network, partnering closely with life science commercial, real world evidence and clinical development teams to bring cutting edge research including trials and quality improvement initiatives to their centers. For life science partners, OncoLens brings a diverse, community focused network of centers to address real world evidence, diversity and inclusion in trials or finding patients with extremely rare genomic alterations or conditions.
“Healthcare is a prime target for AI-driven innovation. Paired with the appropriate solutions, there’s incredible potential for AI to deliver useful and actionable results,” said Mark Buffington, Managing Director and CEO of BIP Capital. “We’re excited about how OncoLens continues to build impressive growth by delivering groundbreaking insights alongside innovative and AI-enabled usability tools like provider-targeted alerts.”
“We’re excited by the growth of OncoLens’ network of domestic and international customers. These cancer centers and lifescience companies alike are closing the current disparities in care with the help of the company’s cutting edge solutions.” says Donna Parr, Managing Partner at Cross Border Impact Ventures.
“The past few years have been a true partnership with our provider and lifescience customers, working closely together to ensure we are able to deliver on the promise of the right treatment at the right time for every cancer patient, whether that patient is a needle in the haystack with an extremely rare genetic alteration or was one among too many that got missed for a clinical trial they were eligible for,” says Anju Mathew, CEO of OncoLens. “We have a bold vision to impact cancer care and excited to continue to deliver to that vision.”
About BIP Capital
BIP Capital is recognized as one of the most active venture investors in the Southeast, serving entrepreneurs, investors, and operators to grow the emerging company ecosystem. It applies experience and process to make investment decisions and operational recommendations, allowing its portfolio companies to achieve and stay on a glide path of growth. Areas of focus include Enterprise SaaS, Healthcare IT, Digital Media, Dev Tools, and MarTech.
About Cross Border Impact Ventures (CBIV)
CBIV is an impact venture capital firm on a mission to revolutionize venture capital investing in health technology. Our firm invests in world-class companies that create better health technologies benefiting women, children and adolescents inclusively and globally. We target venture returns for our investors and empower our portfolio companies to reach beyond their primary markets in the United States and Europe to reach more vulnerable populations in developing economies. We work collaboratively with the CEOs of our portfolio companies to enable commercial success, promote gender and health access equality with creative approaches tailored to local contexts.
About OncoLens
OncoLens is a leading provider of digital health solutions designed to optimize cancer treatment planning. Serving more than 225 cancer centers in the U.S. and internationally, OncoLens also collaborates closely with pharmaceutical and diagnostic companies through the OncoLens Research Network. This collaboration bridges the gap between cancer centers and industry enabling the right treatment at the right time for patients. For more information on OncoLens, please visit www.oncolens.com. Follow us on X and LinkedIn.
OncoLens, a leader in optimizing cancer treatment planning, announced the launch of OncoLens Analytics and its advanced Patient ID solutions. The new solutions mark a significant breakthrough, enabling healthcare providers to deliver timely, precision care for cancer patients through real-time patient identification for clinical trials and key services.
ATLANTA, Sept. 18, 2024 /PRNewswire-PRWeb/ — OncoLens’ innovative solutions operate under three core pillars to achieve their mission of the right treatment at the right time: data interoperability, multidisciplinary collaboration and actionable informatics. By integrating data from multiple sources, including electronic medical records (EMR) and laboratory results, OncoLens identifies key patterns in patient clinical information. This integration provides healthcare teams with real-time alerts and reports for various use cases, including identifying patients who match or are tracking to match clinical trial criteria, are eligible for advanced therapies like CAR-T, or may have missed critical biomarkers.
As cancer care becomes more complex with the rapid proliferation of hyper-targeted therapies and ever-shifting guidelines, healthcare providers face mounting challenges in ensuring optimal care. Large, distributed healthcare systems and networks with multiple facilities also struggle with patient leakage, where patients are referred out of the system rather than being directed to in-house resources. This issue is especially prevalent in clinical trials, where Principal Investigators (PIs) struggle to inform colleagues about available trials and identify patients for trials, and pharmaceutical companies are challenged to meet trial accrual goals.
“Our models are customized to each health system’s dataset, enabling OncoLens to deliver precise solutions and become a vital extension of cancer care teams.”
OncoLens addresses these challenges by leveraging AI/NLP, a proprietary oncology-focused knowledge model, and integrations with key EMR and lab systems to deliver timely alerts and reports. Alongside its other tools, including OncoLens Conference and Collaborate, this solution allows clinical trial teams, nurse navigators, and providers to track patients effectively and ensure follow-through via tumor boards and timely sharing of patient information across care teams.
“Our models are customized to each health system’s dataset, enabling OncoLens to deliver precise solutions and become a vital extension of cancer care teams,” said Anju Mathew, CEO of OncoLens. The solution has already proven invaluable in identifying patients early who have missed essential germline or somatic testing, helping to reduce time to treatment and aligning with value-based healthcare models.
About OncoLens
OncoLens is a leading provider of digital health solutions designed to optimize cancer treatment planning. Serving more than 225 cancer centers in the U.S. and internationally, OncoLens also collaborates closely with pharmaceutical and diagnostic companies through the OncoLens Research Network. This collaboration bridges the gap between cancer centers and industry enabling the right treatment at the right time for patients.
Patients who should receive guideline-recommended genetic testing are often missed due to complex guidelines, discretionary referral practices, inefficient charting processes and siloed data and care teams. Consequently, patients who are candidates for precision therapeutics are overlooked and families cannot characterize patterns of heritability and risk, resulting in suboptimal treatments and strategies.
OncoLens Advanced Patient ID offers a solution to these challenges by efficiently analyzing vast amounts of patient data within a health system’s EHR records, ensuring criteria like family history are not overlooked and enabling timely identification and intervention for patients and family members.
Proactively and automatically identifying eligible patients increases the probability of patients receiving appropriate testing and potential life-saving targeted therapies.
OncoLens Advanced Patient ID utilizes Large Language Models and AI to identify patients who have not yet received guideline-recommended testing needed to detect germline mutations as well as somatic and/or acquired mutations like ESR1, etc. Consolidated reports of patients who may need additional testing are generated by OncoLens and delivered directly to the care team, reducing review time by ≈ 75%. By proactively and automatically identifying eligible patients, especially those with specific criteria such as family history (for germline testing), or cancer type/staging/tumor characteristics (for somatic testing), OncoLens increases the probability of patients receiving appropriate testing and potential life-saving targeted therapies.
A Case Study
A community cancer center recently deployed OncoLens’ Advanced Patient ID to streamline their review of breast cancer patients who were missed for genetic testing. The Patient ID report found 65% of potentially eligible patients (50 of 76) had no history of germline testing, and specifically one triple-negative breast cancer patient “Susan.”
The Patient ID report found 65% of potentially eligible patients (50 of 76) had no history of germline testing.
Susan, a 64-year-old triple-negative breast cancer patient, was identified by the Patient ID report as potentially eligible for genetic testing due to meeting NCCN guidelines and having no previous test results. Upon further review by the care team, Susan initially declined genetic testing due to financial concerns despite NCCN guideline recommendations to test patients with triple negative status and a significant family history of breast cancer. Because she initially declined testing, she was likely missed for any follow up review. This is significant, because biomarker testing can uncover patients with specific mutations who may benefit from targeted therapies such as PARP inhibitors which have demonstrated the potential to reduce disease recurrence by as much as 42%1. Additionally, Susan’s family could miss out on predictive testing, early intervention, and/or risk-reducing options. Through utilizing OncoLens’ Advanced Patient ID, Susan was correctly flagged as eligible for genetic testing and the community center’s social workers are following up with her to provide education and explore testing options.
References
1 Carbognin, L., Sperti, E., Galvano, A., Guzzardo, V., Zambelli, M., Veronese, N., & Bria, E. (2023). Systematic review and meta-analysis of PD-1/PD-L1 inhibitors in combination with chemotherapy for the treatment of advanced or metastatic triple-negative breast cancer. Annals of Oncology, 33(12), 1250-1268. https://www.sciencedirect.com/science/article/pii/S0923753422041655
Results of a quality improvement program to increase complete lung cancer biomarker testing rates by focusing on system, physician, and other factors associated with adverse health outcomes.
Authors: Dwight Earl Heron, Jean Blair, Jawad Elias Francis, Kristina Stoeppler-Biege, Lijo Simpson, Jeremy Stapp, Joseph Kim
Organizations: Bon Secours Mercy Health, Youngstown, OH, AdventHealth, Orlando, FL, Bon Secours St. Francis Cancer Center, Greenville, SC, Atlanta Cancer Care, Decatur, GA, OncoLens, Atlanta, GA, Q Synthesis LLC, Newtown, PA
Broad Based NGS Testing and Targeted Therapies in Multidisciplinary Care Teams (MDT)
In a Life Science company sponsored Quality Improvement Project, OncoLens brought together an NCI center, a regional IDN, and a community cancer center to assess the current practices and insights into local barriers to testing.
The project subsequently addressed these barriers resulting in the overall improvement of NGS testing and targeted therapies in solid tumors possessing a rare gene fusion.
Complete our quick form to download and read the full case study.
Quality improvement project (QIP) with three cancer centers results in double digit improvement in biomarker testing and targeted therapy recommendations.
This case study focuses on a quality improvement project aimed at increasing next-generation sequencing (NGS) testing and discussions of targeted therapies in cancer centers. The study involved three cancer centers and implemented interventions such as targeted alerts, educational handouts, and quality improvement metrics.
Complete our quick form to download and read the full case study.
Hear a national thought leader discuss the impact of liquid biopsy and concurrent biomarker testing for the appropriate care of patients with NSCLC
Brought to you by: CAP TODAY
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Presenter: Zin Htway, PhD, MBA
Program Objectives
Discuss impact of biomarket testing for appropriate care of patiens with NSCLC
Review potential benefits of integrating liquid biopsy with standard-of-care tissue testing on turnaround time and identification of patients with actionable biomarkers in metastatic NSCLC
Explore patient case scenarios that demonstrate potential successes and implementation considerations for concurrent liquid biopsy integration in metastatic NSCLC
FEATURED SPEAKER:
Zin Htway, PhD, MBA
Supervisor and Operations Manager
Anatomic Pathology at HCA
Los Robles Hospital and Medical Center
Apr 11, 2024 | 12:00 PM ET
Liquid Biopsy and Concurrent Testing Strategies for Patients with Metastatic NSCLC
For this fifth installment of a six-webinar series, join us to hear how Dr. Ryan of the Virginia Mason Medical Center is utilizing surgical optimization as part of a multidisciplinary approach to 3D Cell Culture Chemosensitivity in HGG Patients.
High-grade glioma (HGG) patients have extremely poor prognoses. Limited diagnostic tools to accurately predict treatment responses leads to challenges in selecting effective therapeutic options. This interactive discussion will feature real world clinical cases presented by Dr. Roby Ryan of the Virginia Mason Medical Center, where a new functional precision oncology assay was used to direct therapy. Attendees will have the opportunity to participate in an interactive Q&A with Dr. Ryan.
This Functional Precision Medicine Webinar Series is powered by OncoLens. On a single, secure platform, OncoLens data science, informatics and advanced collaboration tools provide a first of a kind platform for targeted treatment planning and confident clinical decision making.
Watch Session Cases Individually
Case #1 — 25 yo male with large left frontal lesion No significant past medical history 6 months of progressive headaches Several weeks of personality changes, then new onset seizure
Case #2 — 74 yo female with left temporal lesion Several months of progressive cognitive impairment Several days of pronounce confusion Receptive aphasia and mild right side weakness
Case #3 — 61 yo female with left temporal lesion Several months of feeling unwell and word finding difficulty New onset seizure event
Case #4 — 28 yo male with hemorrhagic L temporal lesion No significant PMHX Presented at work with sudden severe headache and LOC Required intubation for airway protection and imaging Right frontal EVD
FEATURED SPEAKER:
Roby Ryan, MD
Neurosurgery
Co-Director of Neuro-Oncology
Virginia Mason Medical Center
High Grade Glioma (HGG) Functional Precision Medicine Webinar Series
In this modern era of precision oncology, several therapies targeting pathways that contribute to metastatic colorectal cancer (mCRC) pathogenesis have emerged, including therapies targeting EGFR, VEGF, and the BRAF kinase. Selecting upfront and sequential treatment by considering patient- and tumor-related factors is key to informed shared decision-making and maximizing clinical benefit for patients. This activity features an expert overview of the significance of tumor sidedness in patients with mCRC, how to effectively utilize molecular testing to determine an appropriate course of treatment, and sequencing strategies across the mCRC spectrum.
Director, The Ruesch Center for the Cure of GI Cancers
Frederick P. Smith Endowed Chair
Chief Medical Officer
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, District of Columbia
Target Audience
This activity has been designed to meet the educational needs of oncologists, pathologists, radiologists, oncology nurses, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the care of patients with mCRC.
Learning Objectives
Upon completion of this activity, participants should be better able to:
Implement tumor genotyping and evaluation of tumor sidedness at mCRC diagnosis based on current evidence, guideline recommendations, and an understanding of the mechanistic rationale
Formulate personalized mCRC treatment plans with targeted therapies that are driven by molecular findings and primary tumor localization and supported by the latest evidence and guideline recommendations using a team-based approach
Treatment for patients with melanoma has been revolutionized by the integration of new immunotherapeutic strategies. Although anti–programmed cell death 1 (PD1) checkpoint inhibitors have greatly improved survival outcomes for many patients with advanced melanoma, effective treatment approaches are greatly needed in the setting of anti-PD1–failed melanoma. In this poor-prognosis patient population, emerging oncolytic virus immunotherapies may offer great promise. This program provides updates on the evolving landscape of oncolytic viruses and summarizes the rationale for their use in challenging treatment settings. Faculty review the latest clinical evidence and discuss the potential positioning of emerging oncolytic viruses within existing treatment paradigms for patients with advanced melanoma.
Melanoma Oncolytic Immunotherapy: An Evolving Therapeutic Landscape
Mar 27, 2024 | 11:45 AM EST
ACTIVITY CHAIR:
Michael Ka Keu Wong MD, PhD, FRCPC
Professor, Melanoma and Cutaneous Malignancies
Medical Executive – MD Anderson Cancer Network
Houston, TX
FACULTY:
Anna Pavlick BSN, MSc, DO, MBA
Weill Cornell Medicine New York, NY
FACULTY:
Douglas B. Johnson MD, MSCI
Vanderbilt University School of Medicine Nashville, TN
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
Review the pathophysiology of advanced melanoma, including consensus definitions for determining anti–programmed cell death 1 (PD1) protein resistance.
Describe the mechanism of action of oncolytic virus technology and the rationale for its use as a treatment for anti-PD1–failed melanoma.
Summarize the latest clinical evidence on emerging oncolytic viruses for the treatment of patients with anti-PD1–failed melanoma.
Assess the potential positioning of oncolytic viruses within existing treatment paradigms for patients with anti-PD1–failed melanoma.
Target Audience
The intended audience for this activity includes oncologists and other healthcare professionals involved in the management of patients with melanoma.
Accreditation/Designation of Credit
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Vindico Medical Education designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.
Access the telementoring sessions on ACCC website by following the links listed below to benefit from expert faculty advice and clinical case guidance on the optimal use of bispecific antibodies.
Bispecific antibodies, an emerging class of novel immunotherapy agents, have great therapeutic potential; however, they also present barriers to care including unique and serious treatment-related toxicities that can preclude their widespread use in the community practice setting. To provide optimal care to patients being treated with bispecific antibodies, clinicians must understand the unique pharmacology and potential clinical and operational challenges of these agents. Successful administration of bispecific antibodies requires competence and effective collaboration among multidisciplinary providers on the cancer care team.
Beginning in 2020, the Association of Cancer Care Centers (ACCC) initiated research and education focused on the utilization of bispecific antibodies in the community oncology setting. Findings from an ACCC survey illuminated several barriers to using bispecific antibodies; among these, 59% of survey respondents indicated that they had experienced barriers when caring for patients treated with bispecific antibodies. Common challenges cited include transitioning patients from an inpatient to an outpatient setting, managing patients in remote areas, securing insurance coverage, managing side effects, assisting patients with treatment costs, and lacking in-house expertise with the drug class.
To address this growing need, the Association of Cancer Care Centers (ACCC) has launched Project ECHO®️: Evolving Role of Bispecific Antibodies as Cancer Therapy. This initiative fosters opportunities for community oncology programs to participate in tele-mentoring with a virtual team of expert faculty using the Project ECHO®️ model.
Target Audience
Oncologists, oncology advanced practice providers (nurse practitioners, physician assistants), oncology pharmacists, oncology nurses, and other healthcare professionals involved in treating patients with bispecific antibodies as cancer therapy.
Learning Objectives
At the end of this educational activity, participants will be able to:
Address barriers to the awareness, preparedness, adoption, and use of BsAbs for the treatment of cancer
Improve coordination and communication between community hospitals and academic centers to optimize outcomes and ensure safety for patients being treated with BsAbs
Review strategies for providing equitable care for underserved patients receiving cancer immunotherapies
Accreditation/Designation of Credit
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Physicians’ Education Resource®, LLC and the Association of Community Cancer Centers (ACCC). Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians. Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. These live activities are each approved for 1.0 contact hours (0.10 CEU).
Physicians’ Education Resource®, LLC designates each live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours per session.
PTCE designates these knowledge-based activities for a maximum of 1.0 hours each. Credit will be provided to NABP CPE Monitor within 60 days after activity completion.
Steering Committee
Firas El Chaer, MD Assistant Professor of Medicine, Department of Hematology and Oncology University of Virginia Charlottesville, VA
Amelia Hodson, AG-ACNP Nurse Practitioner University of Virginia Charlottesville, VA
Murali Janakiram, MD, MS Associate Professor of Medicine, Department of Hematology & Hematopoietic Cell Transplantation City of Hope National Medical Center Duarte, CA
Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Genentech.
In this case study, discover how a regional IDN, in collaboration with OncoLens and its partners, successfully improved the management of metastatic colorectal cancer (mCRC) through the use of real-world data insights and tumor board embedded physician education.
Oncologists often face challenges in selecting the right biomarker testing platform and interpreting results, leading to suboptimal patient care. By implementing a comprehensive biomarker testing pathway and educating providers on the importance of early testing, the percentage of mCRC patients receiving complete biomarker testing increased significantly. Learn how this success can be replicated across a large hospital system, benefiting patients with mCRC in multiple locations and improving the care of these highly complex patients.
Complete our quick form to download and read the full case study.
For this fourth installment of a six-webinar series, join us to hear how Dr. Odia of the Miami Cancer Institute at Baptist Health South Florida is using 3D Cell culture chemosensitivity results and NGS profiles to maximize outcomes in glioblastoma.
HGG patients have an extremely poor prognosis. Limited diagnostic tools are available to accurately predict treatment responses, leading to challenges in selecting effective therapeutic options. This interactive discussion will feature real world clinical cases, presented by Dr. Odia of the Miami Cancer Institute at Baptist Health South Florida, where a new functional precision oncology assay was used to direct therapy. There will be time for attendees to participate in interactive Q&A.
This Functional Precision Medicine Webinar Series is powered by OncoLens. On a single, secure platform, OncoLens data science, informatics and advanced collaboration tools provide a first of a kind platform for targeted treatment planning and confident clinical decision making.
Watch Session Cases Individually
Case #1 — Recurrence after Chemoradiation 69 yo F p/w balance issues, left facial droop, and left leg weakness Pathology: WHO grade 4 glioblastoma IDH-wildtype, MGMT unmethylated Location: Right temporal lobe Progression @ 1 year
Case #2 — Multifocal Glioblastoma 42 yo F p/w headache, generalized tingling, and facial numbness Pathology: WHO grade 4 glioblastoma IDH-wildtype, MGMT unmethylated Location: Lateral right frontal Progression @ 6 months
Case #3 — BRAF-mutant Glioblastoma 67 yo F with showed seizures Pathology: WHO grade 4 glioblastoma BRAF-V600E mutation Location: Right temporoparietal Progression @ 7 years after treatment holiday
Case #4 — Post-Radiation Changes 62 yo M p/w expressive aphasia Pathology: c/w glioblastoma IDH-wildtype, MGMT methylated Location: Left inferior temporal gyrus
FEATURED SPEAKER:
Yazmin Odia, MD, MS, FAANS
Chief of Neuro-Oncology
Miami Cancer Institute
Baptist Health South Florida
High Grade Glioma (HGG) Functional Precision Medicine Webinar Series
